WebMD changes its financial outlook for '08

Share this article:
WebMD parent company WebMD Health Corp has revised its outlook due to a lack of healthcare advertisers spending money with the firm.

WebMD said it now expects net income for 2008 to be between $29.5 million and $37.5 million, down from prior estimates for profit of $36.5 million to $46 million.

Citigroup analyst Mark Mahaney lowered his outlook on WebMD for 2008. He reiterated a “hold” rating on the stock.

Goldman Sachs analyst Jennifer Watson said the degree of the company's outlook revision and its explanation that drugmakers are hesitant to commit to advertising spend six to 12 months in advance, were quite surprising. 

“The biggest question is whether the slower trends are WebMD-specific or industry-wide,” Watson wrote in a note to clients. “Specifically, we wonder if advertisers are testing lower-cost options, including emerging ad networks that deliver impressions across smaller consumer health and beauty sites.”
Stifel Nicolaus & Co.'s George Askew said in an Associated Press report the second revision is “incredibly frustrating” given that WebMD's pharma and healthcare-related advertising customers are generally believed to be less economically sensitive than the overall advertising community. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?